Stock AnalizVeradermics, Inc MANE
Biotechnology: Pharmaceutical Preparations · IPO 2026 · data as of November 13, 2026
Veradermics, Inc (MANE) is a healthcare company listed in the US with a market value of about $5.5B.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Score: 0.6 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | 2025 | 2024 |
|---|---|---|
| Revenue | — | — |
| Net income | -$70M | -$26M |
| Free cash flow | -$72M | -$24M |
| EPS (diluted) | $-111.91 | $-37.05 |
| Net margin | — | — |
| ROIC | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $187.33, 44% above the current price; targets range from $172.00 to $204.00; the consensus rating is “Strong buy”; expected EPS is $-2.84 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Veradermics pay a dividend?
Not currently.
Is Veradermics a good stock to buy?
We do not give buy or sell advice. Veradermics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.